Literature DB >> 7730968

Detection of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Bacteroides forsythus in an A. actinomycetemcomitans-positive patient population.

M A Listgarten1, M Y Wong, C H Lai.   

Abstract

A population of 33 subjects were selected on the basis that all had tested positive for A, actinomycetemcomitans at some time during the prior 7 years. Most subjects (31/33) belonged to families with a proband with confirmed localized juvenile periodontitis (JP); however, most subjects had no evidence of the typical lesions associated with JP. Two additional subjects with rapidly progressive periodontitis, known to be positive for A. actinomycetemcomitans, were also recruited. The patients with a history of JP had been treated, but were no longer enrolled in a regular maintenance program. With 3 exceptions, the subjects had not received any dental treatment or antibiotics in the past 3 months. One aim of the study was to determine the prevalence of A. actinomycetemcomitans, P. gingivalis, and B. forsythus in this population. The main purpose was to compare the relative sensitivity of various methods for detecting these periodontal pathogens. Pooled subgingival plaque samples were collected from all the mesial surfaces and aliquots of the suspension processed for the detection of A. actinomycetemcomitans by culture and indirect immunofluorescence (IF) to serotypes a, b, and c. P. gingivalis and B. forsythus were monitored with a DNA probe and IF. With culture, A. actinomycetemcomitans was detected in 39.4% of the samples, at a mean level of 0.64% of the cultivable counts. With IF, A. actinomycetemcomitans was detected in 81.8% of the samples, at levels of 0.40, 0.79, and 0.17% of the total counts for serotypes a, b and c respectively. Overall, IF was more likely to detect A. actinomycetemcomitans, P. gingivalis, and B. forsythus than any of the other methods.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730968     DOI: 10.1902/jop.1995.66.2.158

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  7 in total

1.  Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis.

Authors:  Jill E Rogers; Fei Li; Derek D Coatney; Carlos Rossa; Paul Bronson; Jaclynn M Krieder; William V Giannobile; Keith L Kirkwood
Journal:  J Periodontol       Date:  2007-03       Impact factor: 6.993

Review 2.  Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment.

Authors:  W J Loesche; N S Grossman
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Aggregatibacter actinomycetemcomitans: From Basic to Advanced Research.

Authors:  Abdelhadi Hbibi; Amal Bouziane; Badiaa Lyoussi; Mimoun Zouhdi; Driss Benazza
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Prevalence and quantitative analysis of Epstein-Barr virus DNA and Porphyromonas gingivalis associated with Japanese chronic periodontitis patients.

Authors:  Ayako Kato; Kenichi Imai; Kuniyasu Ochiai; Yorimasa Ogata
Journal:  Clin Oral Investig       Date:  2014-12-18       Impact factor: 3.573

5.  Higher prevalence of Epstein-Barr virus DNA in deeper periodontal pockets of chronic periodontitis in Japanese patients.

Authors:  Ayako Kato; Kenichi Imai; Kuniyasu Ochiai; Yorimasa Ogata
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

6.  Epstein-Barr virus is associated with periodontal diseases: A meta-analysis based on 21 case-control studies.

Authors:  Zilong Gao; Juan Lv; Min Wang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

7.  Detection of Virus Herpes Simplex Type 1 in Patients with Chronic Periodontal Disease.

Authors:  Marija Ivanovska-Stojanoska; Mirjana Popovska; Violeta Anastasovska; Mirjana Kocova; Lidita Zendeli-Bedzeti; Cena Dimova; Angela Taseva
Journal:  Open Access Maced J Med Sci       Date:  2018-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.